3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Carcinoma, Non-Small-Cell Lung
931
Neoplasms
614
Breast Neoplasms
613
Colorectal Neoplasms
460
Neoplasm Metastasis
399
Ovarian Neoplasms
333
Prostatic Neoplasms
316
Melanoma
316
Lung Neoplasms
295
Multiple Myeloma
294
Recurrence
282
Squamous Cell Carcinoma of Head and Neck
248
Stomach Neoplasms
233
Pancreatic Neoplasms
232
Leukemia, Myeloid, Acute
224
Triple Negative Breast Neoplasms
194
Endometrial Neoplasms
190
Carcinoma, Renal Cell
183
Lymphoma, Non-Hodgkin
179
Carcinoma, Hepatocellular
178
Small Cell Lung Carcinoma
166
Leukemia, Lymphocytic, Chronic, B-Cell
158
Advanced Solid Tumors
158
Lymphoma, Follicular
150
Lymphoma, Large B-Cell, Diffuse
141
Urinary Bladder Neoplasms
140
Lymphoma
138
Advanced Solid Tumor
137
Uterine Cervical Neoplasms
136
Head and Neck Neoplasms
134
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Amyloid Neuropathies, Familial
×
1 year
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled